Patents by Inventor Matthew Roy Bull

Matthew Roy Bull has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FGFR kinase inhibitors and pharmaceutical uses
    Patent number: 11192890
    Abstract: Fibroblast Growth Factor Receptor kinase inhibitors and prodrugs thereof of Formula (I) and their use for the treatment of hyper-proliferative diseases such as retinopathy, psoriasis, rheumatoid arthritis, osteoarthritis, septic arthritis, tumour metastasis, periodontal disease, corral ulceration, proteinuria, coronary thrombosis from atherosclerotic plaque, aneurismal aorta, dystrophobic epidermolysis bullosa, degenerative cartilage loss following traumatic joint injury, osteopenias mediated by MMP activity, tempero mandibular joint disease, and demyelating disease of the nervous system.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: December 7, 2021
    Assignees: AUCKLAND UNISERVICES LIMITED, GUANGZHOU INSTITUTE OF BIOMEDICINE AND HEALTH
    Inventors: Adam Vorn Patterson, Jeffrey Bruce Smaill, Amir Ashoorzadeh, Christopher Paul Guise, Christopher John Squire, Swarnalatha Akuratiya Gamage, Maria Rosaria Abbattista, Matthew Roy Bull, Angus Cheverton Grey, Xueqiang Li, Ke Ding, Xiaomei Ren, Shuang Jiang, Zhengchao Tu
  • FGFR KINASE INHIBITORS AND PHARMACEUTICAL USES
    Publication number: 20200017491
    Abstract: Fibroblast Growth Factor Receptor kinase inhibitors and prodrugs thereof of Formula (I) and their use for the treatment of hyper-proliferative diseases such as retinopathy, psoriasis, rheumatoid arthritis, osteoarthritis, septic arthritis, tumour metastasis, periodontal disease, corral ulceration, proteinuria, coronary thrombosis from atherosclerotic plaque, aneurismal aorta, dystrophobic epidermolysis bullosa, degenerative cartilage loss following traumatic joint injury, osteopenias mediated by MMP activity, tempero mandibular joint disease, and demyelating disease of the nervous system.
    Type: Application
    Filed: March 2, 2018
    Publication date: January 16, 2020
    Applicants: Auckland Uniservices Limited, Guangzhou Intitute of BioMedicine and Health
    Inventors: Adam Vorn PATTERSON, Jeffrey Bruce SMAILL, Amir ASHOORZADEH, Christopher Paul GUISE, Christopher John SQUIRE, Swarnalatha Akuratiya GAMAGE, Maria Rosaria ABBATTISTA, Matthew Roy BULL, Angus Cheverton GREY, Xueqiang LI, Ke DING, Xiaomei REN, Shuang JIANG, Zhengchao TU
  • Kinase inhibitor prodrug for the treatment of cancer
    Patent number: 10507210
    Abstract: Compositions containing and methods of administering TH-4000 are useful in treatment of cancer alone or in combination with other anti-cancer agents.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: December 17, 2019
    Assignee: Auckland UniServices Limited
    Inventors: Adam Vorn Patterson, Jeffrey Bruce Smaill, Shevan Silva, Christopher Paul Guise, Matthew Roy Bull, Victoria Jackson, Tillman Pearce, Nipun Davar
  • KINASE INHIBITOR PRODRUG FOR THE TREATMENT OF CANCER
    Publication number: 20170360790
    Abstract: Compositions containing and methods of administering TH-4000 are useful in treatment of cancer alone or in combination with other anti-cancer agents.
    Type: Application
    Filed: December 3, 2015
    Publication date: December 21, 2017
    Applicants: Auckland UniServices Limited, Threshold Pharmaceuticals, Inc.
    Inventors: Adam Vorn Patterson, Jeffrey Bruce Smaill, Shevan Silva, Christopher Paul Guise, Matthew Roy Bull, Victoria Jackson, Tillman Pearce, Nipun Davar